Congress of Clinical Rheumatology (CCR)

September 28, 2020

Various drug therapies, including several cytokine blockers, are showing promise in addressing COVID-19 related cytokine storm syndrome, says Dr. Randall Cron of Children’s Hospital of Alabama.

September 23, 2020

Some drugs used to treat lupus and other connective tissue diseases have been shown to increase cardiovascular risks. Even so, those drugs remain effective in addressing disease symptoms, and a leading rheumatology researcher has suggested that concerns may not be fully warranted.

September 23, 2020

New algorithms and more combination therapeutics are part of the future of psoriatic arthritis care. That’s according to Arthur Kavanaugh, M.D., a rheumatologist with UC San Diego Health who recently presented at the Congress of Clinical Rheumatology East annual meeting held this month.​

September 22, 2020

Black patients with knee osteoarthritis have worse outcomes than their white counterparts, shows a new study.

September 22, 2020

Cognitive impairment can be an ongoing issue for patients with rheumatic disease, such as lupus. A proper diagnosis includes a battery of tests, says Noa Shwartz, M.D., a physician-researcher with Albert Einstein College of Medicine in New York.

September 21, 2020

Simultaneous use of more than one drug is gaining traction as a treatment strategy for severe lupus symptoms, particularly in people with chronic kidney disease.

September 11, 2020

Report shows that sarilumab may be better at controlling severe and refractory pain in rheumatoid arthritis patients than adalimumab.

September 11, 2020

The investigational JAK inhibitor filgotinib―which is under study as a treatment for a number of rheumatic diseases―has been shown to be safe and well tolerated in psoriatic arthritis patients.

June 05, 2015

(CCR 2015) A number of new osteoporosis treatments are on the near horizon, drawing on a new understanding of bone biology, as described by a speaker at the Clinical Congress of Rheumatology.

June 03, 2015

(CCR2015) Nearly 100 new molecules are in development as RA treatments. This summary of a recent presentation by the ever-eloquent Ed Keystone MD gives a brief rundown of their mechanisms, progress, and potential.